Central Nervous System (CNS) diseases represent the largest andfastest growing area of unmet medical need since an alarmingincrease in brain disease incidence is going on. Despite majoradvances in neuroscience, many potential therapeutic agentsare denied access to the CNS because of the existence of aphysiological low permeable barrier, the Blood-Brain Barrier(BBB). To obtain an improvement of drug CNS performance,sophisticated approaches such as nanoparticulate systems arerapidly developing. In particular, in this chapter, the most recentdata demonstrating the potential of lipid nanostructures, suchas Solid Lipid Nanoparticles (SLN) and Nanostructured LipidCarriers (NLC), to transport drugs successfully into the brainfor the treatment of CNS diseases including Alzheimer’s andParkinson’s diseases, cancer, mood disorder, AIDS, and bacterialinfections, are summarised. Their use as drug delivery systemsis associated with many advantages that include an excellentstorage stability, a relatively easy production without the useof any organic solvent, the possibility of steam sterilizationand lyophilization, and large scale production. Moreover, SLNand NLC are obtained by using physiologically well-toleratedingredients already approved for pharmaceutical applicationsin humans and show low toxicity when administered. Becauseof their small size, these systems may be injected intravenouslyand avoid the uptake of macrophages of mononuclear phagocytesystem (MPS). Moreover, their lipophilic features lead them toCNS by an endocytotic mechanism, overcoming the BBB.
|Title of host publication||Nanomedicine and The Nervous System|
|Number of pages||22|
|Publication status||Published - 2012|